en · de · es
cardarine-notes.peptides8425.com › Info › Background And Regulatory Status — Common Mistakes

Background And Regulatory Status — Common Mistakes

By Editorial Desk · published 2025-09-01 · last reviewed 2025-09-22 · Info

This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-09-22 and is reviewed periodically as new material appears.

Background and Regulatory Status

Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.

Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.

Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.

Mechanism and Research Context

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

Cardarine at a glance

PropertyValueNotes
IUPAC name{4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acidSystematic name for GW501516
CAS Registry Number317318-70-0Unique identifier for the parent compound
Molecular formulaC21H18F3NO3S2Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur
Molecular weight453.5 g/molApproximate value for the neutral form
AppearanceWhite to off-white powderTypical description for purified laboratory material

Identity and Pharmacological Classification

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.

Related pages on this site

Detection, Regulation, and Quality Context

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Mechanism and Detection Methods

Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.

GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.

Identity and Pharmacological Mechanism

The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.

Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.

Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.

Supporting material

Michael Bailey, who found that homosexuality had a genetic possibility; Laura Allen and Roger Gorski of UCLA had conducted research on the anterior commissure; molecular geneticist Cassandra Smith; the editor of The Arizona Republic. Directed by Jeremy Taylor, produced by Oliver Morse, made by Windfall Films 18 October Antichaos, about order out of chaos, with Ian Stewart of the University of Warwick; Canadian mathematician Brian Goodwin of the Open University, and emergence; the American biologist Stuart Kauffman of the Santa Fe Institute, and Boolean networks; the Danish theoretical physicist Per Bak of Brookhaven National Laboratory; Christopher Langton of the Santa Fe Institute; the American ecologist Tom Ray of the University of Delaware; the economist W. Brian Arthur of Stanford University; J. Doyne Farmer of the Prediction Company; and the American physicist Thomas Valone (a writer on bioelectromagnetics) of the University of New Mexico. Narrated by Alun Lewis, directed by Yavar Abbas, produced by Geoff Deehan, made by Union Pictures 25 October The Strange Case of Crop Circles 2, showing what had changed from the previous documentary broadcast on 27 October 1991. Directed by Jill Freeman, produced by Michael Wills, made by Juniper Productions 1 November Zen on Wheels, about how Japanese car manufacturers moved a team to Newport Beach, California at the Toyota Calty Design Research, to find out what appealed to buyers of BMW and Mercedes cars, which resulted in the Lexus LS, which outsold Mercedes-Benz and BMW.

== Discovery == Studies conducted in the 1970s found that a series of N-formylmethionine-containing oligopeptides, including the most potent and best known member of this series, N-formylmethionine-leucyl-phenylalanine (fMLF or fMet-Leu-Phe), stimulated rabbit and human neutrophils by an apparent receptor-dependent mechanism to migrate in a directional pattern in classical laboratory assays of chemotaxis. Since these oligopeptides were produced by bacteria or synthetic analogs of such products, it was suggested that the N-formyl oligopeptides are important chemotactic factors and their receptors are important chemotactic factor receptors that act respectively as signaling and signal-recognizing elements to initiate inflammation responses in order to defend against bacterial invasion. Further studies defined a receptor for the N-formyl oligopeptides, formyl peptide receptor (FPR), so named based on its ability to bind and become activated by the oligopeptides. Two receptors where thereafter discovered and named FPR1 and FPR2 based on the similarity of their genes' predicted amino acid sequence to that of FPR rather than on any ability to bind or be activated by the formyl oligopeptides.

A consequence of all this high concentration organ content is that plasma vitamin C is not a good indicator of whole-body status, and people may vary in the time needed to show symptoms of deficiency when consuming a diet low in vitamin C. Excretion (via urine) is as ascorbic acid and metabolites. The fraction that is excreted as unmetabolized ascorbic acid increases as intake increases. In addition, ascorbic acid converts (reversibly) to DHA and from that compound non-reversibly to 2,3-diketogulonate and then oxalate. These three metabolites are also excreted via urine. During times of low dietary intake, vitamin C is reabsorbed by the kidneys rather than excreted. This salvage process delays onset of deficiency. Humans are better than guinea pigs at converting DHA back to ascorbate, and thus take much longer to become vitamin C deficient.

=== Family history and genetics === Positive family history is a risk factor for glaucoma. The relative risk of having primary open-angle glaucoma is increased about two- to four-fold for people who have a sibling with glaucoma. Glaucoma, particularly primary open-angle glaucoma, is associated with mutations in several genes, including MYOC, ASB10, WDR36, NTF4, TBK1, and RPGRIP1. Many of these genes are involved in critical cellular processes that are implicated in the development and progression of glaucoma, including regulation of intraocular pressure, retinal ganglion cell health, and optic nerve function. Normal-tension glaucoma, which comprises 30-90% of primary open-angle glaucoma (depending on ethnic group), is also associated with genetic mutations (including OPA1 and OPTN genes). Additionally, some rare genetic conditions increase the risk of glaucoma, such as Axenfeld-Rieger syndrome and primary congenital glaucoma, which is associated with mutations in CYP1B1 or LTBP2. They are inherited in an autosomal recessive fashion. Axenfeld-Rieger syndrome is inherited in an autosomal dominant fashion and is associated with PITX2 or FOXC1.

== Prognosis == Necrobiosis Lipoidica is classically chronic, difficult to manage, and treat. The prognosis is not reassuring. Squamous cell carcinoma is often a concern with NL. However, this occurs very late into the diagnosis Treatment can typically stop the growth of lesions and ulcers. Lesion treatment is often exquisitely painful and requires intensive wound care. Aesthetically, wounds rarely heal without scarring.

Sources: en.wikipedia.org

Supporting material

== Production == Unlike plutonium-238, plutonium-239, plutonium-240, plutonium-241, and plutonium-242, plutonium-244 is not produced in quantity by the nuclear fuel cycle, because further neutron capture on plutonium-242 produces plutonium-243 which has a short half-life (~5 hours) and quickly beta decays to americium-243 before having much opportunity to further capture neutrons in any but very high neutron flux environments. The global inventory of 244Pu is about 20 grams. Plutonium-244 is also a minor constituent of thermonuclear fallout, with a global 244Pu/239Pu fallout ratio of (5.7 ± 1.0) × 10−5.

==== Chamber ==== The chamber is highly polished and contains insulation, internally. It is manufactured with stainless steel and contains multiple shelves for holding the product. A hydraulic or electric motor is in place to ensure the door is vacuum-tight when closed.

=== Gaining strength === Liu Wenhui took advantage of the Sichuanese conflicts to gain power. In 1924, he gave financial support to Liu Xiang and Yang Sen in their campaign to oust Xiong Kewu's forces; in return, the two warlords allowed him to take control of a part of the defeated Xiong's army and territories. In October 1925, after Yang Sen's defeat in a military conflict, Liu again incorporated part of the losing party's armies and territories, expanding his influence to Meishan and Leshan. Chief Executive Duan Qirui also appointed him as the Assistant Military Affairs Commissioner for Sichuan. When his former commander Chen Hongfan was attacked by Yang Sen's forces, Liu offered him no help and even refused an appeal by Leng Yingdong to let Chen serve in his government. Instead, Liu absorbed Chen's remaining forces; Chen subsequently returned to Dayi County in disgrace and reportedly went mad. During the May Thirtieth Movement, students in Yibin staged a boycott of British goods and clashed with British merchants. Liu Wenhui's military police arrested the student leaders, sparking outrage, but Liu met with the students and made an anti-imperialist speech mentioning his connections to the patriot Jiang Baili. To prove that his prisoners were not being tortured, Liu let demonstrators observe that they were playing basketball in the prison courtyard. In the wake of the Northern Expedition and the First United Front, Liu began flirting with progressive ideas. Around 1926, Liu appointed Communist Party member Liu Yuan'an as one of his senior advisors.

To promote better consistency between a trial's objective and analysis methods, the International Committee for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) has published a new international trial regulatory guidance in Nov 2019, the ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials. The guidance calls for clearly defining the research question of a trial by specifying its estimand. An estimand is a clear description of the treatment effect a trial aims to quantify. The guidance provides a structured framework for defining estimands, which consists of five attributes: (i) population of patients; (ii) treatment conditions being compared; (iii) the endpoint; (iv) the summary measure; and (v) how intercurrent events are handled. Tutorials on how to implement the estimand framework is available.

Sources: en.wikipedia.org

Supporting material

=== Regulation === The early 20th century brought increased regulation of all manner of narcotics, including paregoric, as the addictive properties of opium became more widely understood, and "patent medicines came under fire largely because of their mysterious compositions". In the United States, the Pure Food and Drug Act of 1906 required that certain specified drugs, including alcohol, cocaine, heroin, morphine, and cannabis, be accurately labeled with contents and dosage. Previously many drugs had been sold as patent medicines with secret ingredients or misleading labels. Cocaine, heroin, cannabis, and other such drugs continued to be legally available without prescription as long as they were labeled. It is estimated that sale of patent medicines containing opiates decreased by 33% after labeling was mandated. In 1906 in Britain and in 1908 in Canada laws requiring disclosure of ingredients and limitation of narcotic content were instituted. The U.S. Harrison Narcotics Tax Act of 1914 restricted the manufacture and distribution of opiates, including laudanum and coca derivatives; this was followed by France's Loi des stupefiants in 1916 and Britain's Dangerous Drugs Act in 1920. The Harrison Narcotics Tax Act regulated "opium or coca leaves, or any compound, manufacture, salt, derivative or preparation thereof", but not some medical products containing relatively low concentrations of these substances. Paregoric was classified as an "Exempt Narcotic", as were other medical products containing small amounts of opium or their derivatives.

Following the 1494 Treaty of Tordesillas, the land now called Brazil was claimed for the Portuguese Empire on 22 April 1500, with the arrival of the Portuguese fleet commanded by Pedro Álvares Cabral. Along the coast, the Portuguese encountered various Indigenous communities, most of whom spoke languages of the Tupi–Guarani family. Though the first settlement, São Vicente, was founded in 1532, colonization effectively began in 1534, when King John III of Portugal divided the territory into the fifteen private and autonomous captaincies. However, the decentralized and unorganized captaincy system proved unsuccessful, and in 1549 the Portuguese king restructured them into the Governorate General of Brazil in the city of Salvador, which became the capital of a single and centralized Portuguese colony in South America. In the first two centuries of colonization, Indigenous and European groups lived in constant war, establishing opportunistic alliances in order to gain advantages against each other.

2 CaSO4 + 2 SiO2 + C → 2 CaSiO3 + 2 SO2 + CO2 Until the 1970s commercial quantities of sulfuric acid and cement were produced by this process in Whitehaven, England. Upon being mixed with shale or marl, and roasted, the sulfate liberated sulfur dioxide gas, used in sulfuric acid production, the reaction also produced calcium silicate, a precursor in cement production. On a laboratory scale, the action of hot concentrated sulfuric acid on copper turnings produces sulfur dioxide.

Mechanical tenderization, such as pounding or piercing. The tenderization that occurs through cooking, such as braising. Tenderizers in the form of naturally occurring enzymes known as proteases, which can be added to food before cooking. Examples of enzymes used for tenderizing: papain from papaya, trypsin and chymotrypsin from honey, bromelain from pineapple and actinidain from kiwifruit. Marinating the meat with vinegar, wine, lemon juice, buttermilk or yogurt. Brining the meat in a salt solution (brine). Dry aging of meat at 0 to 2 °C (32 to 36 °F). Velveting Sodium bicarbonate

===== Surface area ===== The general trend in MOFs used for hydrogen storage is that the greater the surface area, the more hydrogen the MOF can store. High surface area materials tend to exhibit increased micropore volume and inherently low bulk density, allowing for more hydrogen adsorption to occur.

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine approved for human use?

No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.

Why is cardarine banned in sport?

It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.

What is the difference between cardarine and GW501516?

Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.

How does cardarine work in the body?

It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.

Network